<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34376229</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1752-1947</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical case reports</Title>
          <ISOAbbreviation>J Med Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recurrent Hurthle cell thyroid carcinoma does not preclude long-term survival: a case report and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>399</StartPage>
          <MedlinePgn>399</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">399</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-021-02987-z</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Follicular thyroid carcinoma is the second most common malignancy of the thyroid gland. In 2016, the so-called Hurthle cell thyroid carcinoma, formerly known as the oxyphilic variant of the follicular thyroid carcinoma, was reclassified by the World Health Organization as a separate pathological entity, which accounts for approximately 3% of all thyroid cancers. Although Hurthle cell thyroid carcinomas are known for their more aggressive tumor biology, metastases are observed in a minority of cases, and long-term survival can be expected. However, disseminated disease is often associated with poor outcome.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">In the presented case, a 63-year-old Caucasian female was incidentally diagnosed with Hurthle cell thyroid carcinoma after undergoing hemithyroidectomy for a nodular goiter. Following completion thyroidectomy, two courses of radioactive iodine therapy were administered. After 4 years of uneventful follow-up, the patient gradually developed metastases in five different organs, with the majority representing unusual sites, such as heart, kidney, and pancreas over a course of 14 years. The lesions were either treated with radioactive iodine therapy or removed surgically, depending on iodine avidity.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Follicular and Hurthle cell thyroid carcinoma are known to potentially spread hematogenously to typical sites, such as lung or bones, however; unusual metastatic sites as presented in our case can also be observed. A search of the literature revealed only scattered reports on patients with multiple metastases in unusual locations. Furthermore, the observed long-term survival of our patient is contradictory to the existing data. As demonstrated, recurrent disease may appear years after the initial diagnosis, emphasizing the importance of consistent aftercare. Radioactive iodine therapy, extracorporeal radiation therapy, and surgical metastasectomy are central therapeutic components. In summary, our case exemplifies that thorough aftercare and aggressive treatment enables long-term survival even in recurrent Hurthle cell thyroid carcinoma displaying unusual multisite metastases.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blossey</LastName>
            <ForeName>Richard David</ForeName>
            <Initials>RD</Initials>
            <Identifier Source="ORCID">0000-0002-8142-4782</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany. Blossey.Richard@mh-hannover.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleine-Döpke</LastName>
            <ForeName>Dennis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ringe</LastName>
            <ForeName>Kristina Imeen</ForeName>
            <Initials>KI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pöhnert</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ringe</LastName>
            <ForeName>Bastian</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klempnauer</LastName>
            <ForeName>Jürgen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beetz</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Lower Saxony, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Case Rep</MedlineTA>
        <NlmUniqueID>101293382</NlmUniqueID>
        <ISSNLinking>1752-1947</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018249" MajorTopicYN="Y">Adenoma, Oxyphilic</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013965" MajorTopicYN="N">Thyroidectomy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiac metastasis</Keyword>
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">Follicular thyroid carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Hurthle cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Multisite metastases</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic metastasis</Keyword>
        <Keyword MajorTopicYN="N">Unusual metastases</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34376229</ArticleId>
        <ArticleId IdType="pmc">PMC8356425</ArticleId>
        <ArticleId IdType="doi">10.1186/s13256-021-02987-z</ArticleId>
        <ArticleId IdType="pii">10.1186/s13256-021-02987-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al.  International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control CCC. 2009;20(5):525–531. doi: 10.1007/s10552-008-9260-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10552-008-9260-4</ArticleId>
            <ArticleId IdType="pmc">PMC2788231</ArticleId>
            <ArticleId IdType="pubmed">19016336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306. doi: 10.1056/NEJM199801293380506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199801293380506</ArticleId>
            <ArticleId IdType="pubmed">9445411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013;154(6):1263–71; discussion 71. doi: 10.1016/j.surg.2013.06.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2013.06.029</ArticleId>
            <ArticleId IdType="pubmed">23973114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniels GH. Follicular thyroid carcinoma: a perspective. Thyroid. 2018;28(10):1229–1242. doi: 10.1089/thy.2018.0306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2018.0306</ArticleId>
            <ArticleId IdType="pubmed">30039751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lloyd RVOR, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th edn. International Agency for Research on Cancer; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet (London, England). 2016;388(10061):2783–2795. doi: 10.1016/S0140-6736(16)30172-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)30172-6</ArticleId>
            <ArticleId IdType="pubmed">27240885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL. 2001;63(4):243–249. doi: 10.1159/000055749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000055749</ArticleId>
            <ArticleId IdType="pubmed">11408821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172(6):692–694. doi: 10.1016/S0002-9610(96)00310-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9610(96)00310-8</ArticleId>
            <ArticleId IdType="pubmed">8988680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grani G, Lamartina L, Durante C, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 2018;6(6):500–514. doi: 10.1016/S2213-8587(17)30325-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-8587(17)30325-X</ArticleId>
            <ArticleId IdType="pubmed">29102432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–2273. doi: 10.1002/cncr.21055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21055</ArticleId>
            <ArticleId IdType="pubmed">15856429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67(3):501–508. doi: 10.1210/jcem-67-3-501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem-67-3-501</ArticleId>
            <ArticleId IdType="pubmed">3410936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon JH, Jeon MJ, Kim M, Hong AR, Kim HK, Shin DY, et al.  Unusual metastases from differentiated thyroid cancers: a multicenter study in Korea. PLoS ONE. 2020;15(8):e0238207. doi: 10.1371/journal.pone.0238207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0238207</ArticleId>
            <ArticleId IdType="pmc">PMC7447021</ArticleId>
            <ArticleId IdType="pubmed">32841270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt MM. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016;16:162. doi: 10.1186/s12885-016-2179-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2179-3</ArticleId>
            <ArticleId IdType="pmc">PMC4768323</ArticleId>
            <ArticleId IdType="pubmed">26921186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cipriani NA, Nagar S, Kaplan SP, White MG, Antic T, Sadow PM, et al.  Follicular thyroid carcinoma: how have histologic diagnoses changed in the last half-century and what are the prognostic implications? Thyroid. 2015;25(11):1209–1216. doi: 10.1089/thy.2015.0297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0297</ArticleId>
            <ArticleId IdType="pmc">PMC4948203</ArticleId>
            <ArticleId IdType="pubmed">26440366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirokawa M, Ito Y, Kuma S, Takamura Y, Miya A, Kobayashi K, et al.  Nodal metastasis in well-differentiated follicular carcinoma of the thyroid: its incidence and clinical significance. Oncol Lett. 2010;1(5):873–876. doi: 10.3892/ol_00000154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol_00000154</ArticleId>
            <ArticleId IdType="pmc">PMC3436349</ArticleId>
            <ArticleId IdType="pubmed">22966397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129(2):207–210. doi: 10.1001/archotol.129.2.207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archotol.129.2.207</ArticleId>
            <ArticleId IdType="pubmed">12578450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farina E, Monari F, Tallini G, Repaci A, Mazzarotto R, Giunchi F, et al.  Unusual thyroid carcinoma metastases: a case series and literature review. Endocr Pathol. 2016;27(1):55–64. doi: 10.1007/s12022-015-9410-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-015-9410-7</ArticleId>
            <ArticleId IdType="pubmed">26662609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hugen N, Sloot YJE, Netea-Maier RT, Van de Water C, Smit JWA, Nagtegaal ID, et al.  Divergent metastatic patterns between subtypes of thyroid carcinoma results from the nationwide Dutch pathology registry. J Clin Endocrinol Metab. 2020;105(3):e299–306. doi: 10.1210/clinem/dgz078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgz078</ArticleId>
            <ArticleId IdType="pmc">PMC7112975</ArticleId>
            <ArticleId IdType="pubmed">31641763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9(4):227–247. doi: 10.1677/erc.0.0090227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/erc.0.0090227</ArticleId>
            <ArticleId IdType="pubmed">12542401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, et al.  Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab. 2010;95(4):1516–1527. doi: 10.1210/jc.2009-1536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-1536</ArticleId>
            <ArticleId IdType="pubmed">20156922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paspala A, Kostakis ID, Gaitanidis A, Prodromidou A, Schizas D, Machairas N. Long-term outcomes after hepatic and pancreatic resections for metastases from thyroid cancer: a systematic review of the literature. J Gastrointest Cancer. 2019;50(1):9–15. doi: 10.1007/s12029-018-00196-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12029-018-00196-4</ArticleId>
            <ArticleId IdType="pubmed">30618003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catford SR, Lee KT, Pace MD, Marasco SF, Longano A, Topliss DJ. Cardiac metastasis from thyroid carcinoma. Thyroid. 2011;21(8):855–866. doi: 10.1089/thy.2010.0273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2010.0273</ArticleId>
            <ArticleId IdType="pubmed">21751883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C. Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol. 2005;125(4):438–442. doi: 10.1080/00016480410022822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00016480410022822</ArticleId>
            <ArticleId IdType="pubmed">15823819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stojadinovic A, Shoup M, Ghossein RA, Nissan A, Brennan MF, Shah JP, et al.  The role of operations for distantly metastatic well-differentiated thyroid carcinoma. Surgery. 2002;131(6):636–643. doi: 10.1067/msy.2002.124732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/msy.2002.124732</ArticleId>
            <ArticleId IdType="pubmed">12075176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al.  Follicular thyroid carcinoma with distant metastasis: outcome and prognostic factor. Endocr J. 2014;61(3):273–279. doi: 10.1507/endocrj.EJ13-0437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1507/endocrj.EJ13-0437</ArticleId>
            <ArticleId IdType="pubmed">24420337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid. 2008;18(10):1105–1110. doi: 10.1089/thy.2008.0080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2008.0080</ArticleId>
            <ArticleId IdType="pubmed">18816179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segkos K, Schmidt C, Nabhan F. Isolated liver metastasis in Hürthle cell thyroid cancer treated with microwave ablation. Case Rep Endocrinol. 2017;2017:2790741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5253501</ArticleId>
            <ArticleId IdType="pubmed">28163939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee GM, You JY, Kim HY, Chai YJ, Kim HK, Dionigi G, et al.  Successful radiofrequency ablation strategies for benign thyroid nodules. Endocrine. 2019;64(2):316–321. doi: 10.1007/s12020-018-1829-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-018-1829-4</ArticleId>
            <ArticleId IdType="pubmed">30569260</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
